Furthermore, our in vivo studies with p53/MCA sarcomas demonstrated that using TLR9 agonists in conjunction with radiotherapy significantly outperformed the individual treatments or no treatment in terms of delaying tumor progression. Here, TP53 is linked to sarcoma.